<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949048</url>
  </required_header>
  <id_info>
    <org_study_id>KT1-CLN001</org_study_id>
    <nct_id>NCT04949048</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Performance of Magneto PE Kit</brief_title>
  <official_title>Evaluation of the Safety and Performance of Magneto PE Kit for Endovascular Thrombectomy in Patients With Acute Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magneto Thrombectomy Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Magneto Thrombectomy Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a prospective, multi-center, multinational open labeled, single&#xD;
      armed study to evaluate the safety and performance of the Magneto PE Kit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the safety of Magneto PE Kit</measure>
    <time_frame>48 (±8) hours</time_frame>
    <description>A composite of major adverse events within 48 (± 8) hours of the index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the safety of Magneto PE Kit</measure>
    <time_frame>30 (±3) days</time_frame>
    <description>A composite of major adverse events within 30 (± 3) days of the index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of ease of use during the procedure</measure>
    <time_frame>Procedure</time_frame>
    <description>Ease of use of Magneto PE Kit as assessed by a subjective questionnaire to be completed by the primary operator after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the impact on RV dysfunction (RV/LV ratio)</measure>
    <time_frame>48 (±8) hours</time_frame>
    <description>RV/LV ratio assessment at 48 (±8) hours</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Magneto PE Kit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Magneto PE Kit</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magneto PE Kit</intervention_name>
    <description>All enrolled patients will be treated with Magneto PE Kit</description>
    <arm_group_label>Magneto PE Kit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical signs, symptoms and presentation consistent with acute PE&#xD;
&#xD;
          -  PE symptom duration ≤ 14 days&#xD;
&#xD;
          -  CTA evidence of PE&#xD;
&#xD;
          -  RV/LV ratio ≥ 0.9&#xD;
&#xD;
          -  Heart rate &lt;130 BPM prior to procedure&#xD;
&#xD;
          -  Subject medically eligible for interventional procedure&#xD;
&#xD;
          -  Age ≥ 18 and &lt;75 years&#xD;
&#xD;
          -  Consent process is completed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Thrombolytic use within 14 days&#xD;
&#xD;
          -  Known bleeding diathesis or coagulation disorder&#xD;
&#xD;
          -  Any contraindication to systemic therapeutic doses of heparin or other anticoagulants&#xD;
&#xD;
          -  Hemodynamic collapse at presentation&#xD;
&#xD;
          -  Decompensated heart failure&#xD;
&#xD;
          -  Presence of Extra-Corporeal Membrane Oxygenation.&#xD;
&#xD;
          -  Major trauma ISS&gt; 15 within 14 days&#xD;
&#xD;
          -  Cardiovascular or pulmonary surgery within last 7 days&#xD;
&#xD;
          -  FiO2 requirement &gt; 40% or &gt; 6 LPM to keep oxygen saturation &gt; 90%&#xD;
&#xD;
          -  Hematocrit &lt; 28%&#xD;
&#xD;
          -  Platelets &lt; 100,000/µL&#xD;
&#xD;
          -  Serum creatinine &gt; 1.8 mg/dL&#xD;
&#xD;
          -  INR&gt;2&#xD;
&#xD;
          -  Left bundle branch block&#xD;
&#xD;
          -  PAP &gt; 70 mmHg m&#xD;
&#xD;
          -  Imaging evidence suggests subject is not appropriate for mechanical thrombectomy&#xD;
&#xD;
          -  Presence of intracardiac lead in right ventricle or atrium.&#xD;
&#xD;
          -  Pacemaker or Implantable Cardioverter Defibrillator&#xD;
&#xD;
          -  Presence of intracardiac thrombus&#xD;
&#xD;
          -  Anaphylactic reaction to radiographic contrast agents that cannot be pre-treated&#xD;
&#xD;
          -  Known right- to-left shunt,&#xD;
&#xD;
          -  Known left ventricular ejection fraction ≤ 30%&#xD;
&#xD;
          -  History of severe chronic pulmonary arterial hypertension&#xD;
&#xD;
          -  History of underlying lung disease with oxygen dependence&#xD;
&#xD;
          -  History of chest irradiation&#xD;
&#xD;
          -  History of Heparin Induced Thrombocytopenia (HIT)&#xD;
&#xD;
          -  Female who is pregnant or nursing&#xD;
&#xD;
          -  Current participation in another investigational drug or device treatment study&#xD;
&#xD;
          -  Life expectancy of &lt; 90 days as determined by the investigator&#xD;
&#xD;
          -  Subjects who are intubated&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shelly Sharon</last_name>
    <phone>0765300768</phone>
    <email>shelly@magts.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aarhus Univeristy Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Asger Andersen, Dr.</last_name>
      <email>asger.andersen@clin.au.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>David Palner, Dr.</last_name>
      <phone>03-5302441</phone>
      <email>Planer@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Amit Segev, Prof.</last_name>
      <phone>03-5302604</phone>
      <email>Amit.Segev@sheba.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

